β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2

β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2

The inhibitors for EGF receptor tyrosine kinase (EGFR-TKIs) such as gefitinib have been used as a standard treatment for non-small cell lung cancer (NSCLC), but the increasingly occurrence of drug resistance, the associated adverse effects and the enrichment of cancer stem cells significantly impede...

Full description

Bibliographic Details
Main Authors: Haibo Cheng, Xiaoyin Ge, Shiqin Zhuo, Yanan Gao, Bo Zhu, Junfeng Zhang, Wenbin Shang, Dakang Xu, Weihong Ge, Liyun Shi
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Pharmacology
Subjects:
elemene
gefitinib
lung cancer
stemness
EZH2
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01413/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2018.01413/full

Similar Items